CISTERNA BIOLOGICS, INC.

Biotech · Private

Platform technology using engineered yeast cells and advanced chromatography to manufacture messenger RNA (mRNA) at reduced cost

Grants
$975K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Development of a Novel Platform for Cost-Efficient mRNA Production in Yeast$274,980
Federal grantDepartment of Health and Human Services · Phase I · Rapid and Ultra-Pure mRNA Production with Next-Generation RNA Polymerases$350,000
Federal grantDepartment of Health and Human Services · Phase I · A Novel Approach to Eliminate Length Impurities for High-Quality mRNA Production$349,746
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2269PranaX Corp—$10M
2270Lilac Therapeutics——
2271IMMUNYX PHARMA USA INC.——
2272CISTERNA BIOLOGICS, INC.——
2273INPHASOL INC.——
2274SYNVEST IMAGING INC.——
2275EdenRoc Sciences LLC—$194M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • Method of purifying mRNA using substrate dependent ribozyme and solid-support attachment tagapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.